SCOPUS 정보 검색 플랫폼

Lancet

Volumn 358, Issue 9293, 2001, Pages 1638-1641

Modulating the profit motive to meet needs of the less-developed world

(3) Schieppati, Arrigo b Remuzzi, Giuseppe a Garattini, Silvio b

a Negri Bergamo Laboratories (Italy)

b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEW DRUG; ORPHAN DRUG;

BUDGET; CLINICAL RESEARCH; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; ENZYME REPLACEMENT; GENE THERAPY; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MARKETING; PATIENT CARE; POLYCYTHEMIA; PREVALENCE; PRIORITY JOURNAL; PROFIT; REVIEW; SOCIOECONOMICS; TUBERCULOSIS;

EID: 0035841614 PISSN: 01406736 EISSN: None Source Type: Journal
DOI: 10.1016/S0140-6736(01)06658-2 Document Type: Review

Times cited : (17)

References (22)

1
- 0034682156
- Uneasy alliance: Clinical investigators and the pharmaceutical industry
- (2000) N Eng J Med , vol.342 , pp. 1539-1544
- Bodenheimer, T.¹

2
- 0004245789
- Washington DC
- (1989) Report of the National Commission on Orphan Diseases

3
- 0029021863
- Trends in drug development costs, times, and risks
- (1995) Drug Inf J , vol.29 , pp. 375-384
- Di Masi, J.A.¹

4
- 0028895424
- Research and development costs for new drugs by therapeutic class
- (1995) Pharmacoeconomics , vol.7 , pp. 152-169
- Di Masi, J.A.¹ Hansen, R.W.² Grabowski, H.G.³ Lasagna, L.⁴

5
- 0028788896
- The economics of orphan drug policy in the US
- (1995) Pharmacoeconomics , vol.8 , pp. 374-384
- Peabody, J.W.¹ Ruby, A.² Cannon, P.³

6
- 0025762252
- Orphan product: Ongoings, progress, and prospects
- (1991) Annu Rev Pharmacol , vol.31 , pp. 603-620
- Haffner, M.E.¹

7
- 85031476655
- Orphan Drug Act. Pub. Law No. 97-414, 96 Stat. 2049
- (1983)

8
- 0006755079
- The inauguration of a system for the promotion of orphan drug development
- (1994) Jap Bioind Letters , vol.11 , pp. 5-6

9
- 85031488341
- January
- (1998) The Australian orphan drug programme

10
- 0003187521
- Regulation (EC) No 141/2000 of the European Parliament and of the Council of December 16, 1999 concerning the orphan medicinal product
- (2000) Off J Eur Comm , vol.18 , pp. 1-5

11
- 85031483805
- (2000) Neglected disease, orphaned drug. MSF International Activity Report

12
- 85031478389
- Industry and industry failing AIDS victims
- July 21
- (2000) Financial Times
- 'T Hoen, E.¹

13
- 85031477321
- Drugmakers drop AIDS suit against South Africa
- April 20
- (2001) Int Herald Tribune
- Swarns, R.L.¹

14
- 0035962302
- South Africa moral victory
- (2001) Lancet , vol.357 , pp. 1303

15
- 85031487080
- Medicine merchants: A special report
- May 21
- (2000) New York Times
- McNeil, D.¹

16
- 0032791853
- Is orphan drug status beneficial to tropical diseases control? Comparison of the American and future European orphan drug acts
- (1999) Trop Med Int Health , vol.4 , pp. 412-420
- Trouiller, P.¹ Battistella, C.² Pinel, J.³ Pecoul, B.⁴

17
- 0039830077
- Access to essential drugs in poor countries: A lost battle?
- (1999) JAMA , vol.281 , pp. 361-367
- Pecoul, B.¹ Chirac, P.² Trouiller, P.³ Pinel, J.⁴

18
- 0003321289
- Yes, drugs for the poor - And patents as well
- Feb 22
- (2001) Int Herald Tribune
- Moore, M.¹

19
- 85031482239
- Health care in the developing world

20
- 0029987569
- Trials to assess equivalence: The importance of rigorous methods
- (1996) BMJ , vol.313 , pp. 36-39
- Jones, B.¹ Jarvis, P.² Lewis, J.A.³

21
- 0030814329
- Equivalence trials
- (1997) N Engl J Med , vol.337 , pp. 1159-1161
- Ware, J.H.¹ Antam, E.M.²

22
- 0031473381
- Are me-too drugs justified?
- (1997) J Nephrol , vol.33 , pp. 283-294
- Garattini, S.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.